These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 10426152)

  • 1. A study of the HLA-DR region in clinical subgroups of multiple sclerosis and its influence on prognosis.
    McDonnell GV; Mawhinney H; Graham CA; Hawkins SA; Middleton D
    J Neurol Sci; 1999 May; 165(1):77-83. PubMed ID: 10426152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic association studies of tumour necrosis factor alpha and beta and tumour necrosis factor receptor 1 and 2 polymorphisms across the clinical spectrum of multiple sclerosis.
    McDonnell GV; Kirk CW; Middleton D; Droogan AG; Hawkins SA; Patterson CC; Graham CA
    J Neurol; 1999 Nov; 246(11):1051-8. PubMed ID: 10631637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of association of transforming growth factor (TGF)-beta 1 and beta 2 gene polymorphisms with multiple sclerosis (MS) in Northern Ireland.
    McDonnell GV; Kirk CW; Hawkins SA; Graham CA
    Mult Scler; 1999 Apr; 5(2):105-9. PubMed ID: 10335519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of interleukin-4 receptor alpha chain variants in multiple sclerosis.
    Hackstein H; Bitsch A; Bohnert A; Hofmann H; Weber F; Ohly A; Linington C; Mäurer M; Poser S; Rieckmann P; Bein G
    J Neuroimmunol; 2001 Feb; 113(2):240-8. PubMed ID: 11164908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of HLA-DRB1 alleles on susceptibility and outcome of a Portuguese Multiple Sclerosis population.
    Silva AM; Pereira C; Bettencourt A; Carvalho C; Couto AR; Leite MI; Marta M; Freijo M; Costa PP; Mendonça D; Monteiro L; Armas JB; Martins B
    J Neurol Sci; 2007 Jul; 258(1-2):69-74. PubMed ID: 17412364
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined effect of HLA-DRB1*1501 and interleukin-1 receptor antagonist gene allele 2 in susceptibility to relapsing/remitting multiple sclerosis.
    de la Concha EG; Arroyo R; Crusius JB; Campillo JA; Martin C; Varela de Seijas E; Peña AS; Clavería LE; Fernandez-Arquero M
    J Neuroimmunol; 1997 Dec; 80(1-2):172-8. PubMed ID: 9413274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HLA class II susceptibility to multiple sclerosis among Ashkenazi and non-Ashkenazi Jews.
    Kwon OJ; Karni A; Israel S; Brautbar C; Amar A; Meiner Z; Abramsky O; Karussis D
    Arch Neurol; 1999 May; 56(5):555-60. PubMed ID: 10328250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The presence of glutamic acid at positions 71 or 74 in pocket 4 of the HLA-DRbeta1 chain is associated with the clinical course of multiple sclerosis.
    Greer JM; Pender MP
    J Neurol Neurosurg Psychiatry; 2005 May; 76(5):656-62. PubMed ID: 15834022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HLA-DRB1 associations with disease susceptibility and clinical course in Australians with multiple sclerosis.
    Stankovich J; Butzkueven H; Marriott M; Chapman C; Tubridy N; Tait BD; Varney MD; Taylor BV; Foote SJ; ; Kilpatrick TJ; Rubio JP
    Tissue Antigens; 2009 Jul; 74(1):17-21. PubMed ID: 19392788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Associations of HLA DRB1 alleles with IgG oligoclonal bands and their influence on multiple sclerosis course and disability status.
    Balnytė R; Rastenytė D; Vaitkus A; Skrodenienė E; Vitkauskienė A; Ulozienė I
    Medicina (Kaunas); 2016; 52(4):217-222. PubMed ID: 27515835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiple sclerosis by phenotype in Germany.
    Engelhard J; Oleske DM; Schmitting S; Wells KE; Talapala S; Barbato LM
    Mult Scler Relat Disord; 2022 Jan; 57():103326. PubMed ID: 35158442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HLA-related subpopulations of MS in Japanese with and without oligoclonal IgG bands. Human leukocyte antigen.
    Kikuchi S; Fukazawa T; Niino M; Yabe I; Miyagishi R; Hamada T; Hashimoto SA; Tashiro K
    Neurology; 2003 Feb; 60(4):647-51. PubMed ID: 12601107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HLA-multiple sclerosis association in continental Italy and correlation with disease prevalence in Europe.
    Ballerini C; Guerini FR; Rombolà G; Rosati E; Massacesi L; Ferrante P; Caputo D; Talamanca LF; Naldi P; Liguori M; Alizadeh M; Momigliano-Richiardi P; D'Alfonso S
    J Neuroimmunol; 2004 May; 150(1-2):178-85. PubMed ID: 15081263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of CCR5 delta32 polymorphism on multiple sclerosis susceptibility and disease course.
    Silversides JA; Heggarty SV; McDonnell GV; Hawkins SA; Graham CA
    Mult Scler; 2004 Apr; 10(2):149-52. PubMed ID: 15124759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of HLA-DRB1 allele heterogeneity on disease risk and clinical course in a West Australian MS cohort: a high-resolution genotyping study.
    Wu JS; James I; Wei Qiu ; Castley A; Christiansen FT; Carroll WM; Mastaglia FL; Kermode AG
    Mult Scler; 2010 May; 16(5):526-32. PubMed ID: 20207784
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microsatellite polymorphisms in the gene promoter of monocyte chemotactic protein-3 and analysis of the association between monocyte chemotactic protein-3 alleles and multiple sclerosis development.
    Fiten P; Vandenbroeck K; Dubois B; Van Coillie E; Nelissen I; Van Damme J; Ligers A; Hillert J; Andersson M; Olsson T; Opdenakker G
    J Neuroimmunol; 1999 Mar; 95(1-2):195-201. PubMed ID: 10229131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HLA-DRB1: genetic susceptibility and disability progression in a Spanish multiple sclerosis population.
    Romero-Pinel L; Pujal JM; Martínez-Yélamos S; Gubieras L; Matas E; Bau L; Torrabadella M; Azqueta C; Arbizu T
    Eur J Neurol; 2011 Feb; 18(2):337-342. PubMed ID: 20629714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interaction of HLA-DRB1*1501 allele and TNF-alpha -308 G/A single nucleotide polymorphism in the susceptibility to multiple sclerosis.
    Shahbazi M; Roshandel D; Omidnyia E; Rshaidbaghan A
    Clin Immunol; 2011 Jun; 139(3):277-81. PubMed ID: 21396892
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HLA-DRB1*15 allele influences the later course of relapsing remitting multiple sclerosis.
    Cournu-Rebeix I; Génin E; Leray E; Babron MC; Cohen J; Gout C; Alizadeh M; Perdry H; Semana G; Brassat D; Clerget-Darpoux F; Yaouanq J; Edan G; Rosenheim M; Fontaine B
    Genes Immun; 2008 Sep; 9(6):570-4. PubMed ID: 18615093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heterogeneity at the HLA-DRB1 locus and risk for multiple sclerosis.
    Barcellos LF; Sawcer S; Ramsay PP; Baranzini SE; Thomson G; Briggs F; Cree BC; Begovich AB; Villoslada P; Montalban X; Uccelli A; Savettieri G; Lincoln RR; DeLoa C; Haines JL; Pericak-Vance MA; Compston A; Hauser SL; Oksenberg JR
    Hum Mol Genet; 2006 Sep; 15(18):2813-24. PubMed ID: 16905561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.